PerpEquities

Equity · Healthcare

Boston Scientific Corporation (BSX) perpetual futures

BSX perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade BSXUSDT.

Boston Scientific is a global medical technology company that designs and sells innovative medical devices for interventional specialties, including cardiology, rhythm management, neurology, and surgery.

$42.71-1.5%NYSE closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

Collecting venue price data...
venue perp mark · Gate.io (BSX/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/2 live markets
Venues
2
Live markets
1/2
24h volume
$0
Open interest
$48.2K
Best liquidity
$8.5K
Gate.io
Tightest spread
+126.1 bps
Gate.io
Highest volume
$0
Gate.io
Settlement mix
USDT · 2/2
Perp/spot vol.
0.00x
Spot volume $780.9M
OI / float
0.00%
Float $63.2B
Spot performance
1D-1.46%
5D-2.98%
1M-10.88%
6M-31.94%
YTD-55.32%
1Y-55.95%

Venue matrix

2 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
Gate.ioTradeBSX/USDTTrading$42.710.0% APR
0.000% every 8h
+126.1 bps$8.5K$0$48.2KUSDT20x
BingXTradeBSX-USDTWatchlist------USDT-

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: Gate.io

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

BSX

Tightest spread

BSX

Highest volume

BSX

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 6h ago
Market cap
$63.3B
Updated 6h ago
Revenue
$21B
Trailing 12 months
Revenue growth
+6%
Next fiscal year
Profit margin
+17.5%
P/E
17.2
Peer P/E 27.3
Free cash flow
$3.6B
Trailing 12 months
More metrics
Net income
$3.7B
Trailing 12 months
P/S
3.0
Peer P/E
27.3
Similar listed perps
Revenue estimate
$21.2B
Next fiscal year
Earnings
2026-10-28
Revenue est. $5.1B · Updated 6h ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$20.1B
Net margin+14.4%
Free cash flow$3.7B
Net debt$10.4B
2020$9.9B
2021$11.9B
2022$12.7B
2023$14.2B
2024$16.7B
2025$20.1B
PeriodRevenueGrowthNet incomeFCF
2020$9.9B-8%-$82M$1.1B
2021$11.9B+20%$1B$1.3B
2022$12.7B+7%$698M$914M
2023$14.2B+12%$1.6B$1.7B
2024$16.7B+18%$1.9B$2.6B
2025$20.1B+20%$2.9B$3.7B
PeriodGross marginOperating marginNet marginROEROA
2020+56.2%+6.1%-0.8%-0.5%-0.3%
2021+62.8%+16.2%+8.7%+6.3%+3.2%
2022+60.8%+14.4%+5.5%+4.0%+2.1%
2023+62.0%+15.3%+11.2%+8.3%+4.5%
2024+61.3%+15.7%+11.1%+8.5%+4.7%
2025+69.0%+19.8%+14.4%+11.9%+6.6%
PeriodCashDebtNet debtCurrent ratio
2020$1.7B$9.5B$7.8B1.82
2021$1.9B$9.5B$7.5B1.48
2022$928M$9.3B$8.4B1.51
2023$865M$9.5B$8.6B1.32
2024$414M$11.1B$10.7B1.08
2025$2B$12.4B$10.4B1.62
PeriodMarket capEnterprise valueP/SP/E
2020$50.9B$58.7B5.1-442.7
2021$60.4B$67.9B5.161.3
2022$66.2B$74.5B5.2103.1
2023$84B$92.6B5.953.5
2024$131.4B$142.2B7.870.9
2025$141.2B$151.5B7.048.6
Q3 2024$4.2B
Q4 2024$4.6B
Q1 2025$4.7B
Q2 2025$5.1B
Q3 2025$5.1B
Q4 2025$5.3B
Q1 2026$5.2B
Q2 2026$5.4B
PeriodRevenueGrowthNet incomeFCF
Q3 2024$4.2B+19%$469M$698M
Q4 2024$4.6B+22%$566M$1.2B
Q1 2025$4.7B+21%$674M$354M
Q2 2025$5.1B+23%$793M$1.1B
Q3 2025$5.1B+20%$755M$1.2B
Q4 2025$5.3B+16%$668M$1B
Q1 2026$5.2B+12%$1.3B$171M
Q2 2026$5.4B+8%$907M$1.3B
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+62.9%+16.0%+11.1%+2.3%+1.2%
Q4 2024+58.6%+12.9%+12.4%+2.6%+1.4%
Q1 2025+63.3%+19.2%+14.5%+3.0%+1.7%
Q2 2025+67.7%+16.2%+15.7%+3.5%+1.9%
Q3 2025+69.9%+20.7%+14.9%+3.2%+1.8%
Q4 2025+74.5%+22.8%+12.6%+2.8%+1.5%
Q1 2026+69.4%+20.6%+25.7%+5.2%+3.0%
Q2 2026+70.7%+21.6%+16.7%+3.6%+2.0%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$2.5B$11.3B$8.8B1.48
Q4 2024$414M$11.1B$10.7B1.08
Q1 2025$725M$11.7B$11B1.45
Q2 2025$534M$12B$11.5B1.37
Q3 2025$1.3B$12B$10.8B1.51
Q4 2025$2B$12.4B$10.4B1.62
Q1 2026$1.5B$11B$9.5B1.90
Q2 2026$539M$12.6B$12.1B1.24
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$123.4B$132.2B29.365.8
Q4 2024$131.7B$142.4B28.958.2
Q1 2025$149B$160B32.055.3
Q2 2025$158.8B$170.3B31.449.7
Q3 2025$144.7B$155.4B28.647.9
Q4 2025$141.4B$151.7B26.753.0
Q1 2026$93.2B$102.7B17.917.4
Q2 2026$63.1B$75.1B11.617.2

Refreshed 6h ago

Charts: revenue, profit, cash flow & valuation
Revenue$5.4BQ2 2026
$1.4B$2.7B$4.1B$5.4BQ3 2023: $3.5BQ4 2023: $3.7BQ1 2024: $3.9BQ2 2024: $4.1BQ3 2024: $4.2BQ4 2024: $4.6BQ1 2025: $4.7BQ2 2025: $5.1BQ3 2025: $5.1BQ4 2025: $5.3BQ1 2026: $5.2BQ2 2026: $5.4BQ3 2023Q2 2026
Net income$907MQ2 2026
$334.3M$668.5M$1B$1.3BQ3 2023: $504MQ4 2023: $504MQ1 2024: $494MQ2 2024: $324MQ3 2024: $469MQ4 2024: $566MQ1 2025: $674MQ2 2025: $793MQ3 2025: $755MQ4 2025: $668MQ1 2026: $1.3BQ2 2026: $907MQ3 2023Q2 2026
EBITDA$1.4BQ2 2026
$400.8M$801.5M$1.2B$1.6BQ3 2023: $976MQ4 2023: $885MQ1 2024: $984MQ2 2024: $812MQ3 2024: $1.1BQ4 2024: $1.1BQ1 2025: $1.2BQ2 2025: $1.4BQ3 2025: $1.4BQ4 2025: $1.3BQ1 2026: $1.6BQ2 2026: $1.4BQ3 2023Q2 2026
Free cash flow$1.3BQ2 2026
$259M$599M$939M$1.3BQ3 2023: $492MQ4 2023: $690MQ1 2024: -$81MQ2 2024: $658MQ3 2024: $698MQ4 2024: $1.2BQ1 2025: $354MQ2 2025: $1.1BQ3 2025: $1.2BQ4 2025: $1BQ1 2026: $171MQ2 2026: $1.3BQ3 2023Q2 2026
EPS$0.61Q2 2026
$0.23$0.45$0.68$0.9Q3 2023: $0.34Q4 2023: $0.34Q1 2024: $0.33Q2 2024: $0.22Q3 2024: $0.32Q4 2024: $0.38Q1 2025: $0.45Q2 2025: $0.53Q3 2025: $0.5Q4 2025: $0.45Q1 2026: $0.9Q2 2026: $0.61Q3 2023Q2 2026
Cash / Debt$539MQ2 2026
$3.2B$6.3B$9.5B$12.6BQ3 2023 · Cash: $952MQ3 2023 · Debt: $9.3BQ4 2023 · Cash: $865MQ4 2023 · Debt: $9.5BQ1 2024 · Cash: $2.3BQ1 2024 · Debt: $11BQ2 2024 · Cash: $2.9BQ2 2024 · Debt: $10.9BQ3 2024 · Cash: $2.5BQ3 2024 · Debt: $11.3BQ4 2024 · Cash: $414MQ4 2024 · Debt: $11.1BQ1 2025 · Cash: $725MQ1 2025 · Debt: $11.7BQ2 2025 · Cash: $534MQ2 2025 · Debt: $12BQ3 2025 · Cash: $1.3BQ3 2025 · Debt: $12BQ4 2025 · Cash: $2BQ4 2025 · Debt: $12.4BQ1 2026 · Cash: $1.5BQ1 2026 · Debt: $11BQ2 2026 · Cash: $539MQ2 2026 · Debt: $12.6BQ3 2023Q2 2026
CashDebt
Profitability+70.7%Q2 2026
+18.6%+37.2%+55.9%+74.5%Q3 2023 · Gross margin: +61.4%Q4 2023 · Gross margin: +62.1%Q1 2024 · Gross margin: +61.8%Q2 2024 · Gross margin: +62.7%Q3 2024 · Gross margin: +62.9%Q4 2024 · Gross margin: +58.6%Q1 2025 · Gross margin: +63.3%Q2 2025 · Gross margin: +67.7%Q3 2025 · Gross margin: +69.9%Q4 2025 · Gross margin: +74.5%Q1 2026 · Gross margin: +69.4%Q2 2026 · Gross margin: +70.7%Q3 2023 · Operating margin: +15.8%Q4 2023 · Operating margin: +15.0%Q1 2024 · Operating margin: +16.7%Q2 2024 · Operating margin: +18.1%Q3 2024 · Operating margin: +16.0%Q4 2024 · Operating margin: +12.9%Q1 2025 · Operating margin: +19.2%Q2 2025 · Operating margin: +16.2%Q3 2025 · Operating margin: +20.7%Q4 2025 · Operating margin: +22.8%Q1 2026 · Operating margin: +20.6%Q2 2026 · Operating margin: +21.6%Q3 2023 · Net margin: +14.3%Q4 2023 · Net margin: +13.5%Q1 2024 · Net margin: +12.8%Q2 2024 · Net margin: +7.9%Q3 2024 · Net margin: +11.1%Q4 2024 · Net margin: +12.4%Q1 2025 · Net margin: +14.5%Q2 2025 · Net margin: +15.7%Q3 2025 · Net margin: +14.9%Q4 2025 · Net margin: +12.6%Q1 2026 · Net margin: +25.7%Q2 2026 · Net margin: +16.7%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Revenue growth+7.5%Q2 2026
+5.7%+11.4%+17.1%+22.8%Q2 2024: +14.5%Q3 2024: +19.3%Q4 2024: +22.4%Q1 2025: +20.9%Q2 2025: +22.8%Q3 2025: +20.3%Q4 2025: +15.9%Q1 2026: +11.6%Q2 2026: +7.5%Q3 2023Q2 2026
Shares outstanding1.5BQ2 2026
374M747.9M1.1B1.5BQ3 2023: 1.5BQ4 2023: 1.5BQ1 2024: 1.5BQ2 2024: 1.5BQ3 2024: 1.5BQ4 2024: 1.5BQ1 2025: 1.5BQ2 2025: 1.5BQ3 2025: 1.5BQ4 2025: 1.5BQ1 2026: 1.5BQ2 2026: 1.5BQ3 2023Q2 2026
Valuation17.2Q2 2026
21.743.465.086.7Q3 2023 · P/E: 38.3Q4 2023 · P/E: 42.0Q1 2024 · P/E: 50.5Q2 2024 · P/E: 86.7Q3 2024 · P/E: 65.8Q4 2024 · P/E: 58.2Q1 2025 · P/E: 55.3Q2 2025 · P/E: 49.7Q3 2025 · P/E: 47.9Q4 2025 · P/E: 53.0Q1 2026 · P/E: 17.4Q2 2026 · P/E: 17.2Q3 2023 · P/S: 21.9Q4 2023 · P/S: 22.7Q1 2024 · P/S: 25.9Q2 2024 · P/S: 27.3Q3 2024 · P/S: 29.3Q4 2024 · P/S: 28.9Q1 2025 · P/S: 32.0Q2 2025 · P/S: 31.4Q3 2025 · P/S: 28.6Q4 2025 · P/S: 26.7Q1 2026 · P/S: 17.9Q2 2026 · P/S: 11.6Q3 2023Q2 2026
P/EP/S
Revenue$20.1B2025
$5B$10B$15.1B$20.1B2018: $9.8B2019: $10.7B2020: $9.9B2021: $11.9B2022: $12.7B2023: $14.2B2024: $16.7B2025: $20.1B20182025
Net income$2.9B2025
$1.1B$2.3B$3.5B$4.7B2018: $1.7B2019: $4.7B2020: -$82M2021: $1B2022: $698M2023: $1.6B2024: $1.9B2025: $2.9B20182025
EBITDA$5.1B2025
$1.3B$2.6B$3.8B$5.1B2018: $2.6B2019: $2.2B2020: $1.5B2021: $2.5B2022: $2.7B2023: $3.5B2024: $3.9B2025: $5.1B20182025
Free cash flow$3.7B2025
$910M$1.8B$2.7B$3.7B2018: -$6M2019: $1.4B2020: $1.1B2021: $1.3B2022: $914M2023: $1.7B2024: $2.6B2025: $3.7B20182025
EPS$1.942025
$0.77$1.63$2.48$3.332018: $1.192019: $3.332020: -$0.082021: $0.692022: $0.452023: $1.072024: $1.252025: $1.9420182025
Cash / Debt$2B2025
$3.1B$6.2B$9.3B$12.4B2018 · Cash: $146M2018 · Debt: $7B2019 · Cash: $217M2019 · Debt: $10.3B2020 · Cash: $1.7B2020 · Debt: $9.5B2021 · Cash: $1.9B2021 · Debt: $9.5B2022 · Cash: $928M2022 · Debt: $9.3B2023 · Cash: $865M2023 · Debt: $9.5B2024 · Cash: $414M2024 · Debt: $11.1B2025 · Cash: $2B2025 · Debt: $12.4B20182025
CashDebt
Profitability+69.0%2025
+16.6%+34.1%+51.6%+69.0%2018 · Gross margin: +65.9%2019 · Gross margin: +64.1%2020 · Gross margin: +56.2%2021 · Gross margin: +62.8%2022 · Gross margin: +60.8%2023 · Gross margin: +62.0%2024 · Gross margin: +61.3%2025 · Gross margin: +69.0%2018 · Operating margin: +17.7%2019 · Operating margin: +15.9%2020 · Operating margin: +6.1%2021 · Operating margin: +16.2%2022 · Operating margin: +14.4%2023 · Operating margin: +15.3%2024 · Operating margin: +15.7%2025 · Operating margin: +19.8%2018 · Net margin: +17.0%2019 · Net margin: +43.8%2020 · Net margin: -0.8%2021 · Net margin: +8.7%2022 · Net margin: +5.5%2023 · Net margin: +11.2%2024 · Net margin: +11.1%2025 · Net margin: +14.4%20182025
Gross marginOperating marginNet margin
Revenue growth+19.9%2025
-0.8%+6.1%+13.0%+19.9%2019: +9.3%2020: -7.7%2021: +19.9%2022: +6.7%2023: +12.3%2024: +17.6%2025: +19.9%20182025
Shares outstanding1.5B2025
373.6M747.3M1.1B1.5B2018: 1.4B2019: 1.4B2020: 1.4B2021: 1.4B2022: 1.4B2023: 1.5B2024: 1.5B2025: 1.5B20182025
Valuation48.62025
-306.3-169.8-33.4103.12018 · P/E: 29.22019 · P/E: 13.42020 · P/E: -442.72021 · P/E: 61.32022 · P/E: 103.12023 · P/E: 53.52024 · P/E: 70.92025 · P/E: 48.62018 · P/S: 5.02019 · P/S: 5.92020 · P/S: 5.12021 · P/S: 5.12022 · P/S: 5.22023 · P/S: 5.92024 · P/S: 7.82025 · P/S: 7.020182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-10-28
Revenue est. $5.1B · Updated 6h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20263.27$21.2B+6%15
FY 20273.40$22.2B+10%15
FY 20283.75$23.7B+18%7
FY 20294.12$25.7B+28%2
FY 20304.52$27.8B+39%4
Q1 20270.80$5.4B+3%8

Company events

6
2026-10-28EarningsActual - / Estimate 0.77-
2026-07-29EarningsActual 0.86 / Estimate 0.84Beat
2026-04-22EarningsActual 0.8 / Estimate 0.79Beat
2026-02-04EarningsActual 0.8 / Estimate 0.78Beat
2025-10-22EarningsActual 0.75 / Estimate 0.71Beat
2025-07-23EarningsActual 0.75 / Estimate 0.73Beat

Peer comparison

Similar listed perps

FMP company data

Company intelligence

Updated: Sep 29, 2026, 12:18 PM UTC

Company profile

Sector
Healthcare
Industry
Medical - Devices
Chief executive
Michael F. Mahoney
Employees
59,000
IPO date
May 19, 1992
Country
US
Exchange
New York Stock Exchange
Website
Altman Z-scorei3.06
Piotroski scorei8/9
FMP ratingiA-
Owner earningsi$1.37B$0.92 per share
ESG risk ratingiBIndustry rank: 15 out of 170

Rating factors

Return on equityi
4
Return on assetsi
5
Debt to equityi
2
Price to earningsi
2
Price to booki
3
Market cap history
$64.90B+0.5%Jun 26 – Sep 26
$64.56B$70.28B$75.99BHigh: $75.99B · 2026-08-17Low: $64.56B · 2026-06-29Latest: $64.90B · 2026-09-25Jun 26Jul 26Aug 26Sep 26
Latest: $64.90B · 2026-09-25High: $75.99B · 2026-08-17Low: $64.56B · 2026-06-29
M&A filings
Largest fund holders
FundWeightShares held
VTI0.1%47.2M
VOO0.11%39.5M
VPMAX1.37%30.9M
FXAIX0.11%20.7M
IVV0.1%18.5M
SPY0.1%17.4M
S5SD.L0.16%11.6M
VGHAX1.24%11.3M
XLV1.03%10.1M
VECP.S0.19%10M
VUG0.11%9.1M
VHCAX1.15%8.8M

Analyst track record

How the analysts covering BSX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings248638
Analysts3135
Buy / hold / sell240 / 8 / 0609 / 29 / 0
Upgrades / downgrades / initiations1 / 5 / 24 / 6 / 5
Price targets hit / missed0 / 227 (0%)0 / 587 (0%)
Avg. return after a rating (TipRanks)-50.1%-51.7%
Best / worst call-9.9% / -69.1%-9.9% / -69.1%

After buy calls on this stock: median 21-day move +1.4% vs S&P 500 -1.8% (n = 623)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Vijay KumarEvercore ISI80% hit rate on this stock · 10 targets measuredBuytarget $55.00Jul 30, 2026
  2. William PlovanicCanaccord Genuity78% hit rate on this stock · 18 targets measuredBuytarget $66.00Jul 30, 2026
  3. Patrick WoodMorgan Stanley75% hit rate on this stock · 16 targets measuredBuytarget $74.00Jul 28, 2026

Latest ratings

DateAnalystCallTarget
Oct 2, 2026Unknown AnalystBernsteinBuyReiterated$54.00
Oct 1, 2026Robbie MarcusJ.P. MorganBuyMaintained$56.00
Oct 1, 2026Robbie MarcusJ.P. MorganBuyMaintained$56.00
Oct 1, 2026Kendall AuRBC CapitalBuyMaintained$70.00
Sep 23, 2026Larry BiegelsenWells FargoHoldReiterated$48.00
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$40.00$60.00$80.00$100$120Nov 25 · Buy 24 · Hold 2 · Sell 0Nov 25Dec 25 · Buy 24 · Hold 2 · Sell 0Jan 26 · Buy 24 · Hold 1 · Sell 0Jan 26Feb 26 · Buy 25 · Hold 1 · Sell 0Mar 26 · Buy 24 · Hold 1 · Sell 0Mar 26Apr 26 · Buy 28 · Hold 1 · Sell 0May 26 · Buy 26 · Hold 3 · Sell 0May 26Jun 26 · Buy 26 · Hold 3 · Sell 0Jul 26 · Buy 26 · Hold 4 · Sell 0Jul 26Aug 26 · Buy 25 · Hold 4 · Sell 0Sep 26 · Buy 22 · Hold 4 · Sell 0Sep 26Oct 26 · Buy 23 · Hold 4 · Sell 0Nov 25 · avg. target $127Dec 25 · avg. target $126Jan 26 · avg. target $124Feb 26 · avg. target $110Mar 26 · avg. target $104Apr 26 · avg. target $91.19May 26 · avg. target $86.46Jun 26 · avg. target $80.76Jul 26 · avg. target $67.89Aug 26 · avg. target $66.28Sep 26 · avg. target $61.83Oct 26 · avg. target $61.50Nov 25 · month-end close $102Dec 25 · month-end close $95.35Jan 26 · month-end close $93.53Feb 26 · month-end close $76.85Mar 26 · month-end close $62.75Apr 26 · month-end close $57.61May 26 · month-end close $48.31Jun 26 · month-end close $42.68Jul 26 · month-end close $46.73Aug 26 · month-end close $48.30Sep 26 · month-end close $43.65Oct 26 · month-end close $42.60

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data via FMP · computed Oct 3, 2026 · 248 ratings

Frequently asked questions

Where can I trade BSX perpetual futures?

Boston Scientific Corporation (BSX) perpetual futures trade on 1 crypto venues, including Gate.io. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade BSX around the clock?

Yes. Unlike the underlying stock, BSX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on BSX perpetuals?

Right now the BSX perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to 0.0% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the BSX perp price compare to the Boston Scientific Corporation stock?

The venue-median BSX perp mark is $42.7 versus a reference stock price of $42.7, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a BSX perpetual future?

A BSX perpetual is a derivative that tracks the price of Boston Scientific Corporation with no expiry date. It lets you take long or short exposure to Boston Scientific Corporation on crypto venues, around the clock.

What is BSXUSDT perpetual?

BSXUSDT is the symbol most crypto exchanges use for the Boston Scientific Corporation perpetual settled in USDT (Tether). It tracks the BSX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

BSX perpetuals · perpequities.comBSX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/bsx-perp"><img src="https://perpequities.com/badge/bsx-perp.svg" width="240" height="64" alt="BSX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of BSX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for BSX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for BSX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X